ObsEva SA to Present Model-Based Analysis Supporting Clinical Use of Linzagolix at Doses Not Requiring Hormonal Add back Therapy

• 13th European Society of Gynecology (ESG) Congress: October 16-19 in Vienna, Austria.

Oral Presentation, Thursday, October 17 at 11:45 a.m. CET

“Is hormonal add-back necessary? A model-based analysis to guide gonadotropin-releasing hormone (GnRH) receptor antagonist use for management of endometriosis and uterine fibroids”

• 10th American Conference on Pharmacometrics (ACoP) meeting: October 20‑23 in Orlando, FL

Poster Presentation, Tuesday, October 22 and Oral Presentation, Wednesday, October 23 at 9 a.m. EDT

“Model-based Dose Selection for a GnRH Receptor Antagonist in Endometriosis and Uterine Fibroids to Reduce Symptoms While Preventing Lumbar Spine Bone Mineral Density Loss”